title: Salvianolic acid A, a polyphenolic derivative from Salvia miltiorrhiza bunge, as a multifunctional agent for the treatment of Alzheimer's disease.
abstract: The effects of Salvianolic acid A (Sal A) on the treatment of Alzheimer's disease (AD) were investigated. Sal A significantly inhibits amyloid beta [Formula: see text] self-aggregation and disaggregates pre-formed [Formula: see text] fibrils, reduces metal-induced [Formula: see text] aggregation through chelating metal ions, and blocks the formation of reactive oxygen species (ROS) in SH-SY5Y cells. Sal A protects cells against [Formula: see text]-induced toxicity. Furthermore, Sal A, possibly because of the effects of decreasing toxicity effects of [Formula: see text] species, alleviates [Formula: see text]-induced paralysis in transgenic Caenorhabditis elegans. Circular dichroism (CD) experiments and Molecular dynamic (MD) simulations demonstrate that Sal A inhibits [Formula: see text] self-aggregation through binding to the C-terminus of [Formula: see text], and therefore stabilizing the [Formula: see text]-helical conformations. Altogether, our data show that Sal A, as the multifunctional agent, is likely to be promising therapeutics for AD.
authors.affiliation: Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
authors.forename: Ying Ying
authors.initials: YY
authors.lastname: Cao
authors.forename: Ling
authors.initials: L
authors.lastname: Wang
authors.forename: Hu
authors.initials: H
authors.lastname: Ge
authors.forename: Xi Lin
authors.initials: XL
authors.lastname: Lu
authors.forename: Zhong
authors.initials: Z
authors.lastname: Pei
authors.forename: Qiong
authors.initials: Q
authors.lastname: Gu
authors.forename: Jun
authors.initials: J
authors.lastname: Xu
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000187:drug effects*; D000818:Animals; D017173:Caenorhabditis elegans / Q000187:drug effects; D002109:Caffeic Acids / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002942:Circular Dichroism; D003300:Copper / Q000737:chemistry; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007501:Iron / Q000737:chemistry; D007502:Iron Chelating Agents; D007773:Lactates / Q000494:pharmacology*; D056004:Molecular Dynamics Simulation; D018384:Oxidative Stress / Q000187:drug effects; D010936:Plant Extracts / Q000494:pharmacology; D058225:Plaque, Amyloid / Q000188:drug therapy*; D017382:Reactive Oxygen Species / Q000037:antagonists & inhibitors; D027561:Salvia miltiorrhiza; D000685:Serum Amyloid A Protein / Q000187:drug effects* / Q000378:metabolism; D015032:Zinc / Q000737:chemistry
chemical_list: D016229:Amyloid beta-Peptides; D002109:Caffeic Acids; D007502:Iron Chelating Agents; D007773:Lactates; D010936:Plant Extracts; D017382:Reactive Oxygen Species; D000685:Serum Amyloid A Protein; C066201:salvianolic acid A; D003300:Copper; D007501:Iron; D015032:Zinc